Natera, Inc. develops and commercializes cell-free DNA and genetic testing for oncology, women’s health and organ health. Company updates commonly cover financial results, revenue trends, laboratory operations and publications supporting tests such as Signatera, Prospera, Panorama and Horizon.
Recurring news also includes oncology molecular residual disease applications, clinical evidence presented at medical meetings, transplant rejection surveillance data, collaborations using Natera assays in drug trials, and patent or litigation developments tied to its MRD technology. The company reports through CLIA-certified and CAP-accredited laboratory operations and through Foresight Diagnostics, its subsidiary.
Natera (NTRA) entered a clinical collaboration agreement with Incyte (INCY) for a phase II study in colorectal cancer. The trial will evaluate Incyte’s investigational bispecific immunotherapy, INCA33890, in patients with stage 2/3 disease who have completed surgery and adjuvant chemotherapy, treatment given after surgery. Natera’s Signatera test will be incorporated as both a primary and secondary endpoint, measures used to assess the study.
After chemotherapy, patients will undergo repeated Signatera testing for up to 12 months. Those testing positive for molecular residual disease (MRD), with no evidence of disease on imaging, may be eligible for enrollment and treatment. Natera will also provide trial matching services based on Signatera MRD status and other eligibility criteria.
Natera (Nasdaq: NTRA) appointed Solomon Moshkevich chief executive officer and a member of its board of directors, effective immediately.
Steve Chapman is stepping down as CEO and will remain a consultant for an extended period and an advisor to the board. Moshkevich joined Natera in 2011 and most recently served as president of clinical diagnostics, following roles across product development and commercial operations. Natera also separately reported third-quarter 2026 financial results, available on its investor relations website.
Natera (NASDAQ: NTRA) reported third-quarter 2026 revenue of $794.0 million, up 34.1% from the same period in 2025. Test volume rose 22.3% to approximately 1,093,100, while oncology tests increased 60.9% to approximately 339,500. Gross margin slipped to 64.7% from 64.9%. Net loss narrowed to $59.9 million, or $0.42 per diluted share, from $87.5 million, or $0.64 per diluted share.
Natera raised its 2026 revenue outlook to $3.005 billion–$3.035 billion, a $140 million increase at the midpoint, and expects positive cash flow. Its gross-margin outlook is approximately 64%–66%. Quarterly operating expenses increased 19.5% to $576.1 million. Cash, cash equivalents and restricted cash totaled approximately $1,097.2 million at September 30, up approximately $5.7 million from June 30. Outstanding debt, including accrued interest, was $80.3 million.
Natera (NASDAQ: NTRA) announced Signatera data linking molecular response with longer survival in patients receiving first-line immunotherapy across four metastatic cancers. The real-world analysis included 424 patients with stage IV melanoma, renal cell carcinoma, microsatellite instability-high colorectal cancer or non-small cell lung cancer.
Complete molecular responders, defined by two consecutive negative Signatera results, had 93.2% overall survival at 36 months, versus 77.9% for other patients (P=0.0003). Survival did not differ significantly between responders continuing immunotherapy and those stopping it: 93.5% versus 89.4% (P=0.42). Natera said the findings support identifying responders who may be able to reduce treatment. The data will be presented at SITC in Phoenix, November 4–8.
Natera (NASDAQ: NTRA) announced three peer-reviewed publications evaluating its Signatera test for recurrence detection and treatment guidance in head and neck cancer.
In a surgical cohort, chemotherapy was associated with a 35% absolute reduction in 2-year locoregional recurrence among Signatera-positive patients: 28.6% versus 63.3% without chemotherapy. Signatera-negative patients showed no outcome differences with chemotherapy. A separate study of 168 patients reported surveillance sensitivity of 95.2%, specificity of 100%, negative predictive value of 99.4% and positive predictive value of 100% across HPV-positive and HPV-negative patients.
A retrospective analysis of 97 patients found recurrence detection a median of 4.3 months before imaging progression, with 91.7% sensitivity and 96.4% specificity. Signatera positivity was the only independent predictor of progression-free survival in that analysis.
Natera (NASDAQ: NTRA) received Medicare coverage for its Signatera molecular residual disease test in hepatocellular carcinoma, a form of liver cancer. Coverage through the Molecular Diagnostics Services Program (MolDX) includes serial surveillance testing for early-stage patients with no post-surgical evidence of disease.
The decision was supported by a real-world study of 125 patients. Signatera showed sensitivity of 83% versus 42% for alpha-fetoprotein (AFP), the guideline-recommended biomarker, and specificity of 100%. These measures describe detection of disease and correct identification of its absence, respectively. Signatera's lead time ahead of imaging was up to 16.5 months, with a median of 7.9 months, versus 2.2 months for AFP.
Natera (NTRA) will release its third-quarter financial results after the market closes on November 5, 2026.
The quarter ended September 30, 2026. A conference call and webcast will follow at 4:30 p.m. ET, with a webcast replay available at investor.natera.com.
Natera (NTRA) reported phase III VOLGA bladder cancer findings linking Signatera Genome blood-test results with event-free survival at ESMO 2026.
The analysis tracked circulating tumor DNA (ctDNA), tumor-derived DNA in blood, before bladder-removal surgery. 24-month event-free survival was 91% among persistently Signatera-negative patients, 81% among initially positive patients whose ctDNA cleared before surgery, and 55% among those remaining positive. Signatera has been evaluated in seven phase III bladder cancer trials.
In resectable stage 2B–3B non-small cell lung cancer, Clarity detected ctDNA in 99% of patients before treatment; clearance before surgery or chemoradiotherapy was associated with 100% one-year event-free survival. Other studies examined Signatera in endometrial and breast cancer, including serial monitoring of minimal residual disease (MRD), cancer traces remaining after treatment.
Natera (NTRA) announced new data presented at ASN Kidney Week 2026, including real-world analyses of chronic kidney disease (CKD). The presentations comprised 18 abstracts, including three oral presentations.
Among patients with newly occurring CKD, the median interval from the first abnormal kidney indicator to documented diagnosis was about 5.3 years. Median estimated kidney filtration rate fell from 75 to 66 mL/min/1.73 m² in the two years before diagnosis. Only one third of patients meeting KDIGO-aligned high-risk criteria had documented nephrology care; those who did waited a median of 149 days. Natera said its Renasight genetic test is designed to clarify the cause of kidney disease and support earlier, more targeted specialist referrals.
Natera (NTRA) will present clinical evidence across 20 abstracts at the ESMO Annual Congress, taking place October 23–26, 2026, in Madrid.
In the ICONIC gastroesophageal cancer trial, Signatera Genome detected all evaluable recurrences during surveillance, with a >7.3-month median lead time over standard imaging. In the phase III SAGITTARIUS colon cancer trial, Signatera results changed providers’ pre-planned treatment for one in three patients; 87% of those patients had treatment reduced based on negative molecular residual disease results, meaning no residual cancer DNA was detected. An analysis of exceptional responders with HER2-positive metastatic breast cancer found 81% had sustained negative results during serial monitoring. In a separate cohort, Signatera complemented by blood-based genomic profiling identified clinically relevant biomarkers in 18 of 50 patients.